Corlentor (ivabradine) is a heart medicine used to treat stable angina pectoris which causes chest pain. It is used in adult patients who do not tolerate or cannot take heart medicines called beta-blockers. It is also used in combination with beta-blockers in adult patients whose condition is not fully controlled with a beta-blocker and whose heart rate is too high (over 60 beats per minute).
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not receive enough oxygen. It usually appears between 40 and 50 years of age. The most common symptom of angina is chest pain or discomfort. Angina is more likely to happen when the heart beats faster in situations such as exercise, emotion, exposure to the cold or after eating. This increase in heart rate can cause the chest pain in people who suffer from angina.
How does Corlentor work?
Corlentor mainly works by reducing the heart rate by a few beats per minute. This lowers the heart’s need for oxygen especially in the situations when an angina attack is more likely to happen. In this way Corlentor helps to control and reduce the number of angina attacks.
Do not take Corlentor
- if you are allergic (hypersensitive) to ivabradine or any of the other ingredients of Corlentor (see “further information” for a list of all ingredients);
- if your resting heart rate before treatment is too slow (below 60 beats per minute);
- if you are suffering from cardiogenic shock (a heart condition treated in hospital);
- if you suffer from a heart rhythm disorder;
- if you are having a heart attack;
- if you suffer from very low blood pressure;
- if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and with or without exertion);
- if you suffer from severe heart failure (when your heart fails to work properly);
- if you have a pacemaker;
- if you suffer from severe liver problems;
- if you are already taking medicines for the treatment of fungal infections (such as ketoconazole, itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin or erythromycin given orally), medicines to treat HIV infections (such as nelfinavir, ritonavir) or nefazodone (medicine to treat depression) (see “Taking other medicines”);
- if you are pregnant;
- if you are breast-feeding.
Take special care with Corlentor
- if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest pain) or sustained atrial fibrillation (a type of irregular heartbeat),
- if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much),
- if you have had a recent stroke (cerebral attack),
- if you suffer from mild to moderate low blood pressure,
- if you suffer from chronic heart failure (when your heart fails to work properly),
- if you suffer from chronic eye retinal disease,
- if you suffer from moderate liver problems,
- if you suffer from severe renal problems. If any of the above applies to you, talk straight away to your doctor before or while taking Corlentor.
Corlentor is not intended for use in children and adolescents younger than 18 years.
Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Make sure to tell your doctor if you are taking any of the following medicines, as a dose adjustment of Corlentor or monitoring should be required:
- diltiazem, verapamil (used for high blood pressure or angina pectoris)
- fluconazole (an antifungal medicine)
- rifampicin (an antibiotic)
- barbiturates (for difficult sleeping or epilepsy)
- phenytoin (for epilepsy)
- Hypericum perforatum or St John’s Wort (herbal treatment for depression)
- QT prolonging medicines to treat either heart rhythm disorders or other conditions :
- quinidine, disopyramide, ibutilide, sotalol, amiodarone (to treat heart rhythm disorders)
- bepridil (to treat angina pectoris)
- certain types of medicines to treat anxiety, schizophrenia or other psychoses (such as pimozide, ziprasidone, sertindole)
- anti-malarial medicines (such as mefloquine or halofantrine)
- intravenous erythromycin (an antibiotic)
- pentamidine (an antiparasitic medicine)
- cisapride (against the gastro-oesophageal reflux)
Taking Corlentor with food and drink
Limit your consumption of grapefruit juice during treatment with Corlentor.
Pregnancy and breast-feeding
Do not take Corlentor if you are pregnant or planning a pregnancy (see “Do not take Corlentor”).If you are pregnant and have taken Corlentor, talk to your doctor.
Do not take Corlentor if you are breast-feeding (see “Do not take Corlentor”).
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Corlentor may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see “Possible side effects”). If this happens to you, be careful when driving or using machines at times when there could be sudden changes in light intensity, especially when driving at night.
Important information about some of the ingredients of Corlentor
Corlentor contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take Corlentor exactly as your doctor has told you.You should check with your doctor or pharmacist if you are not sure. The usual recommended starting dose is one tablet of Corlentor 5 mg twice daily increasing if necessary to one tablet of Corlentor 7.5 mg twice daily. Your doctor will decide the right dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Corlentor 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening.
Corlentor should be taken during meals.
If you take more Corlentor than you should
A large dose of Corlentor could make you feel breathless or tired because your heart slows down too much. If this happens, contact your doctor immediately.
If you forget to take Corlentor
If you forget to take a dose of Corlentor, take the next dose at the usual time. Do not take a double dose to make up for the forgotten dose.
The calendar printed on the blister containing the tablets should help you remember when you last took a tablet of Corlentor.
If you stop taking Corlentor
As the treatment for angina is usually life-long, you should discuss with your doctor before stopping this medicinal product.
If you think that the effect of Corlentor is too strong or too weak, talk to your doctor or pharmacist.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Corlentor can cause side effects, although not everybody gets them.
The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10)
common (affects 1 to 10 users in 100)
uncommon (affects 1 to 10 users in 1,000)
rare (affects 1 to 10 users in 10,000)
very rare (affects less than 1 user in 10,000)
not known (frequency cannot be estimated from the available data)
Luminous visual phenomena (brief moments of increased brightness, most often caused by sudden changes in light intensity).
Modification in the heart functioning (the symptoms are a slowing down of the heart rate), abnormal perception of heartbeat, headache, dizziness and blurred vision.
Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle cramps and changes in laboratory parameters : high blood levels of uric acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a breakdown product of muscle).
Itching, skin rash, skin reddening, low blood pressure, feeling of faintness, syncope.
If any of the side effects gets serious of if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use Corlentor after the expiry date which is stated on the carton and blister after ‘EXP’. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Corlentor is a medicine that contains the active substance ivabradine. It is available as salmon-coloured tablets (oblong: 5 mg; triangular: 7.5 mg). The 5-mg tablets have a score line that enables them to be divided into two equal halves, each containing 2.5 mg ivabradine.
Corlentor is used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort and due to problems with the blood flow to the heart). It is used in adults (aged 18 years or over) with coronary artery disease (obstruction of the blood vessels that supply the heart) who have a normal sinus rhythm (heartbeat). It can be used in the following groups:
- patients who cannot take or tolerate beta-blockers (another type of medicine to treat angina);
- patients whose disease is not controlled with beta-blockers and whose heart rate is above 60 beats per minute. Corlentor is used in combination with beta-blockers in these patients.
The medicine can only be obtained with a prescription.
Corlentor is taken twice a day with meals, once in the morning and once in the evening.
The recommended starting dose is 5 mg twice a day, although 2.5 mg twice a day can be used in patients over the age of 75 years, before the dose is increased to 5 mg twice a day. After three to four weeks of treatment, the dose may be increased to 7.5 mg twice a day depending on the patient’s response.
The symptoms of angina are caused by the heart not receiving enough oxygenated blood. In stable angina, these symptoms appear during physical effort. The active substance in Corlentor, ivabradine, works by blocking the ‘I f currents’ in the sinus node, the ‘pacemaker’ for the heart that controls the heart’s contractions and regulates the heart rate. When these currents are blocked, the heart rate is lowered, so that the heart has less work to do and needs less oxygenated blood. Corlentor therefore reduces or prevents the symptoms of angina.
Corlentor has been studied in five main studies involving over 4,000 adults with long-term stable angina. The medicine was compared with placebo (a dummy treatment) in 360 patients, atenolol (a beta-blocker) in 939 patients and amlodipine (another medicine used to treat angina) in 1,195 patients. It was also compared with placebo as an add-on to atenolol in 889 patients and as an add-on to amlodipine in 728 patients. Each study lasted three to four months. The main measure of effectiveness was how long the patients could exercise on a bicycle or a treadmill, measured at the start and the end of each study.
Corlentor was more effective than placebo at improving exercise capacity and was as effective as atenolol and amlodipine. Corlentor was also more effective than placebo when added to atenolol. However, adding Corlentor to amlodipine did not provide an additional benefit.
The most common side effect with Corlentor (seen in more than 1 patient in 10) is luminous phenomena or ‘phosphenes’ (a temporary brightness in the field of vision). For the full list of all side effects reported with Corlentor, see the package leaflet.
Corlentor should not be used in people who may be hypersensitive (allergic) to ivabradine or any of the other ingredients. It must not be used in patients who have a resting heart rate below 60 beats per minute, very low blood pressure, various types of heart disorder (cardiogenic shock, rhythm disorders, heart attack or heart failure) or severe liver problems. It must not be used in women who are pregnant or breast-feeding. For the full list of restrictions, see the package leaflet.
Caution is needed if Corlentor is taken with some other medicines. See the package leaflet for full details.
The CHMP concluded that Corlentor has sufficient effectiveness against angina and an acceptable safety profile for it to provide an alternative treatment for patients who cannot take beta-blockers or whose disease is not controlled with them. The Committee decided that Corlentor’s benefits are greater than its risks and recommended that it be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the European Union for Corlentor to Les Laboratoires Servier on 25 October 2005. The marketing authorisation is valid for an unlimited period.
For more information about treatment with Corlentor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This summary was last updated in 07-2010.